Article Details

Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly ...

Retrieved on: 2022-03-27 04:08:51

Tags for this article:

Click the tags to see associated articles and topics

Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly .... View article details on hiswai:

Excerpt

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up